Boehringer Ingelheim has launched its new-generation thrombolyticMetalyse (tenecteplase) for acute myocardial infarction in the UK, where it is the first licensed drug for thrombolysis that can be given as a bolus injection in under 10 seconds. The firm notes that the availability of the drug should make it easier to meet the UK National Service Framework targets of delivering thrombolysis to AMI patients within 60 minutes of calling for professional help. Tenecteplase has been rolling out in Europe since March and was first launched in the USA last year by partner Genentech (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze